Abhilasha Gupta

Abhilasha Gupta has a wealth of experience in the field of research. Abhilasha began their career in 1998 as a BscHons student at CSIRO, where they investigated the binding nature of insulin receptor to its high affinity ligand, insulin, by genetic complementation. In 2000, they worked as a Graduate Research Assistant at St Vincent's Institute of Medical Research, where they specialized in the body's energy metabolism by AMP-activated protein kinase (AMPK). In 2007, they began a postdoctoral research fellowship at Thomas Jefferson University, where they specialized in gene therapy in two systems: HIV/HCV and Mucopolysaccaridosis type VII (MPS VII)/Sly syndrome (deficient of the Beta-Glucouronidase enzyme). In 2010, they continued their postdoctoral research fellowship at Thomas Jefferson University, where they worked to elucidate the mechanisms by which desmosomal proteins, particularly specialized desmosomal cadherins, desmogleins (Dsg) mediate cell signaling in normal and pathogenic states during skin development. In 2016, they worked as a Research Specialist at the University of Pennsylvania, School of Medicine, where they focused on understanding how to improve the design of genetic switches for gene therapy. Currently, they are a Principal Scientist, Vector Engineering at SwanBio Therapeutics.

Abhilasha Gupta began their educational journey in 1995 when they obtained a BSc in Biochemistry & Molecular Biology and Pathology from the University of Melbourne. In 1999, they received a BSc(Hons) in Molecular Biology and Biochemistry from the same university. Finally, they completed their education in 2005 when they obtained a Phd in Molecular Biology and Biochemistry from St. Vincent's Institute of Medical Research.